SCHEMBL6337406

SCHEMBL6337406

CCC1(CC)C(=O)NC(=O)N1C(=O)c1ccc2ccccc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.45
TSHR P16473 3/20 0.45
NPC1 O15118 3/20 0.43
RAB9A P51151 2/20 0.43
ENPP3 O14638 2/20 0.43
ALPL P05186 2/20 0.43
XIAP P98170 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 1/20 0.43
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
KDM4E B2RXH2 1/20 0.41
PTPN1 P18031 1/20 0.41
HDAC3 O15379 2/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 2/20 0.41
BCHE P06276 1/20 0.41
AKR1C1 Q04828 1/20 0.41
LMNA P02545 2/20 0.41
GMNN O75496 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284939 0.82 HPGD (0.48) HPGDTSHRNPC1RAB9AENPP3
SCHEMBL6284071 0.78 TSHR (0.45) HPGDTSHRNPC1RAB9AENPP3
SCHEMBL6278898 0.75 TSHR (0.44) HPGDTSHRNPC1RAB9AENPP3
SCHEMBL30623333 0.66 SMN1; SMN2 (0.72) HPGDNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL1317943 0.66 SMN1; SMN2 (0.72) HPGDNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4310722 0.65 TSHR (0.84) HPGDTSHRNPC1RAB9AALDH1A1
SCHEMBL11577852 0.64 BCHE (0.56) HPGDTSHRNPC1RAB9AENPP3
SCHEMBL31047697 0.64 BCHE (0.56) HPGDTSHRNPC1RAB9AENPP3
SCHEMBL4108418 0.63 SMN1; SMN2 (0.73) HPGDTSHRNPC1RAB9ASMN1; SMN2
SCHEMBL30848559 0.63 SMN1; SMN2 (0.73) HPGDTSHRNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919365-B2 Imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2005-07-19 US disclosed
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1384715-A1 NOVEL IMIDAZOLIDINEDIONE DERIVATIVES AND USE THEREOF AS DRUGS Senju Pharmaceutical Co., Ltd. (JP) 2004-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs CMA1, TPSD1, TPSB2 HPGD 762/4885TSHR 1021/4885NPC1 1028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.